Enanta Pharmaceuticals Files 8-K
Ticker: ENTA · Form: 8-K · Filed: May 12, 2025 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Enanta Pharma filed an 8-K on 5/12/25 for financial updates.
AI Summary
Enanta Pharmaceuticals, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies a formal update from Enanta Pharmaceuticals to the SEC regarding its financial status and operations, which is crucial for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks.
Key Players & Entities
- ENANTA PHARMACEUTICALS, INC. (company) — Registrant
- 0000950170-25-069155 (filing_id) — Accession Number
- May 12, 2025 (date) — Date of Report
- 4 Kingsbury Avenue, Watertown, Massachusetts 02472 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Enanta Pharmaceuticals?
The primary purpose is to report on Enanta Pharmaceuticals, Inc.'s results of operations and financial condition, as well as to file financial statements and exhibits.
On what date was this 8-K report filed?
The report was filed on May 12, 2025.
What is Enanta Pharmaceuticals, Inc.'s principal executive office address?
The principal executive offices are located at 4 Kingsbury Avenue, Watertown, Massachusetts 02472.
What is the Commission File Number for Enanta Pharmaceuticals, Inc.?
The Commission File Number is 001-35839.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding ENANTA PHARMACEUTICALS INC (ENTA).